Compare DoorDash Inc (DASH) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DoorDash Inc vs IDEXX Laboratories, Inc. — how do they compare? DoorDash Inc trades at $192.17 (market cap $82.86B), while IDEXX Laboratories, Inc. trades at $512.76 (market cap $39.92B). The key difference: DoorDash Inc is far larger — about 2.1× IDEXX Laboratories, Inc.'s market cap, and DoorDash Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DoorDash Inc for 59 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| DASH | IDXX | |
|---|---|---|
Market Cap | $82.86B | $39.92B |
Volume | 2,006,669 | 715,982 |
Sector | Media | Health |
52-Week High | $275.44 | $766.68 |
52-Week Low | $146.60 | $504.70 |
Typical Hold Time | 59 Days | 46 Days |
Enterprise Value | $80.82B | $40.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DoorDash (DASH) trades at $191.24, down 1.23% on the day, with strong analyst support showing 75% buy ratings and a $255.80 consensus price target. The company demonstrates robust revenue growth from $6.6B in 2022 to $13.7B in 2025, achieving profitability with net income of $935M. Recent innovations include AI-powered text ordering and drone delivery expansion, while technical indicators show the stock trading near key support at $190 with overall bullish momentum.
DoorDash presents a compelling growth story with expanding margins and strategic initiatives, though elevated valuation multiples (P/E 100.13) and recent earnings misses warrant caution. The stock offers 34% upside to analyst targets but faces regulatory scrutiny and competitive pressures in the food delivery space. Positive cash flow trends and institutional support provide fundamental strength despite near-term volatility risks.
IDEXX Laboratories (IDXX) trades at $513.14, down 0.44% with bearish technical signals despite strong fundamentals. The company demonstrates robust revenue growth, expanding from $3.4B in 2022 to $4.3B in 2025, with net income reaching $1.06B. Recent acquisitions like CoVetAI and diagnostic platform expansions highlight strategic growth initiatives. Technical indicators show oversold conditions with RSI at 26.58, while moving averages signal bearish momentum. Analyst consensus remains optimistic with a $665 price target representing 30% upside potential.
The outlook remains positive given strong earnings beats, expanding profit margins, and strategic acquisitions. However, risks include technical weakness, FX headwinds, and competitive pressures. With 56.5% analyst buy ratings and institutional accumulation, IDXX offers growth potential but requires monitoring of technical support levels near $492-$502 for entry opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
